Disease activity in systemic lupus erythematosus is closely associated with the appearance of immunoglobulin (Ig)G antibody to native DNA in both humans and mice. Like normal antibody responses, the anti-DNA autoantibody first appears as IgM and then switches to IgG. Structural studies of IgG anti-DNA suggest that these antibodies are the products of clonally selected, specifically stimulated B cells. The origins of the IgM anti-DNA have been less clear. To determine whether the earlier appearing IgM anti-DNA antibody in autoimmune mice also derives from clonally selected, specifically stimulated B cells or B cells activated by nonselective, polyclonal stimuli, we have analyzed the molecular and serological characteristics of a large number of monoclonal IgM anti-DNA antibodies from autoimmune (NZB x NZW)F1 mice. We have also analyzed IgM and IgG anti-DNA hybridomas obtained from the same individual mice to determine how the later-appearing IgG autoantibody may be related to the earlier-appearing IgM autoantibody within an individual mouse. The results demonstrate that: (a) IgM anti-DNA, like IgG, has the characteristics of a specifically stimulated antibody; (b) IgM and IgG anti-DNA antibodies have similar variable region structures and within individual mice may be produced by B cells derived from the same clonal precursors; (c) recurrent germline and somatically derived VH and VL structures may influence the specificity of anti-DNA monoclonal antibody for denatured vs. native DNA; and (d) the results provide a structural explanation for the selective development of IgG antibody to native DNA as autoimmunity to DNA progresses in (NZB x NZW)F1 mice.
A ntibody to DNA is a manifestation of the autoimmune disease SLE and plays a demonstrable role in disease pathogenesis in both humans (1) and (NZB x NZW)F1 mice (2, 3) . Because of similarities to humans in the development of disease, (NZB x NZW)F1 mice have become useful experimental models for studying the cellular and molecular basis for anti-DNA autoantibody production (3) . In particular, the availability of hybridoma-derived, anti-DNA mAbs from autoimmune mice has provided the opportunity to analyze the structural basis for antibody specificity to DNA (4) . How anti-DNA antibody originates both in human and mouse SLE remains obscure, however.
Previous experiments from our laboratories have concentrated on the analysis of interdonal and intraclonal diversity of spontaneous anti-DNA antibodies within an individual autoimmune (NZB x NZW)F1 mouse (5) (6) (7) . The results from those analyses demonstrated that the IgG anti-DNA antibody within an individual autoimmune mouse had all the characteristics attributable to clonally selected, secondary. immune antibody to specific antigen: IgG isotype, oligoclonality, and V region somatic mutations among donaUy related antibodies. The results also suggested that the antigen most likely to have stimulated such an antibody was DNA. In this regard, anti-DNA in (NZB x NZW)F1 mice appears to be similar to anti-DNA in MRL lpr/Ipr mice (8, 9) . However, the results from at least one study on the clonal heterogeneity of anti-DNA antibody within individual autoimmune (NZB x NZW)F1 mice led to a different conclusion (10) . Although VH 1 and VL gene representation among the hybridomas in the previous study was not consistent with a polyclonal population, the hybridomas were nevertheless clonally diverse. Anti-DNA antibody in autoimmune mice undergoes a spontaneous isotype shift from IgM to IgG (11) (12) (13) . Analyses of B cell activity in (NZB x NZW)F1 mice (14) have led to the hypothesis that at least the initial, IgM stage of anti-DNA autoantibody production is due to polyclonal activation of B cells (15) and that subsequent donal selection of IgG anti-DNA-producing B cells occurs subsequent to this event. However, there have been no direct studies to determine whether IgM anti-DNA autoantibodies have the characteristics of antibody produced by a nonselected, polyclonal population of B cells. Likewise, there have been no studies to directly determine the clonal relationship between the IgM and IgG anti-DNA autoantibodies within individual (NZB x NZW)F1 mice.
The present experiments were proposed to accomplish three major goals. (a) Since there has been some question as to whether the autoimmune anti-DNA antibody in (NZB x NZW)F1 mice is generally oligoclonal and characteristic of an antigen-stimulated, secondary immune response, we extended our analysis of the clonal diversity of IgG anti-DNA antibodies to include seven additional (NZB x NZW)F1 mice. (b) To determine whether the earlier-appearing IgM anti-DNA antibody is also clonally selected and expresses V region structures that are similar to the later-appearing IgG anti-DNA antibodies in autoimmune (NZB x NZW)F1 mice, a large number of IgM anti-DNA hybridomas from four different mice were analyzed. (c) To determine whether the IgG anti-DNA antibody within an individual autoimmune mouse is donally related to the earlier-appearing IgM anti-DNA antibody within the same mouse, IgM and IgG hybridomas from three individual mice were analyzed. The results confirmed our previous results that spontaneous IgG anti-DNA antibodies in (NZB x NZW)F1 mice are generally oligoclonal in origin and have V region structural characteristics consistent with an antigen-selected derivation. The results also demonstrated preferential expression of particular V. and VL genes among IgM anti-DNA hybridomas, suggesting that IgM anti-DNA is also produced by selective B cell stimulation. Finally, the results demonstrated that in general IgM and IgG anti-DNA autoantibody-producing B cells have structurally similar Ig V regions and that within an individual mouse at least some of the IgG anti-DNA antibody-producing B cells are derived from the same clonal precursors as the IgM anti-DNA antibody-producing B cells.
Materials and Methods

Mice and Generation of Hybridomas. (NZB x NZW)Ft mice
were purchased from Harlan/Sprague-Dawley (Indianapolis, IN) and maintained in a pathogen-free environment within the animal facilities at The University of Tennessee, Memphis. Hybridomas were generated as described previously (5) . A partial splenectomy and B cell fusion were performed on one mouse. The mouse was completely anesthetized by a combination of intraperitoneal administration of a mixture of xylazine/ketamine/butorphanol (25: 40:4 mg/kg body weight) and intermittent inhalation of metaphane throughout the surgical procedure. An incision was made in the left flank. The blood vessels in the vascular bundle that enters the hilus of the spleen were simnltaneously sealed and cauterized. The spleen was cut and the free half removed and used to generate hybridomas. The abdominal wall and overlying skin were closed with surgical staples that were removed 10 d after surgery. The remaining half of the spleen was removed at a later date for hybridoma production by the normal procedure.
ELISAforAnti-DNA. The direct-binding, sohd-phase ELISA used to detect anti-DNA-positive culture wells after the fusion and determination of IgH and L isotypes have been described in detail (5) . Culture wells were chosen for cloning of hybridomas only when the relevant culture supernatant produced a relative antibody activity of 3 on a scale of 1 to 10, with 10 being the maximum activity of the assay (OD~0s i>1.2). The supernatants were also screened for binding to micro-ELISA plates that were not coated with DNA but were treated identically otherwise. The source of DNA used for screening hybridoma supernatants was commercial calf thymus DNA sheared by sonication. Only hybrids producing antibody that was positive on DNA-coated plates and negative for binding to plates not coated with DNA were considered for cloning. This screening procedure allowed us to select for hybridomas producing both low-and high-avidity IgM and IgG DNA binding antibodies, as indicated by the data in Table 1 . The assay did not discriminate between ssDNA and dsDNA specificity.
eDNA Sequencing. The procedures for isolation ofmRNA (16) and cDNA sequencing (17) , the sequences of the oligonucleotides used as primers, and the method for sequence comparisons were exactly the same as those we have used previously (7) .
Statistical Analyses. The numbers ofgermline V. and V~ genes that could encode anti-DNA were estimated from the repeat frequencies of individual Vn and V~ observed among all the different clones represented in this study. V. and V~ from individual clones were considered to have been derived from the same germline V. or V~ if the nucleotide sequences were ~95% homologous. The identical pair method of Briles and Carroll (18) was used to obtain the estimates: R = N/A, where N = n(n-1)/2; A = , ~I czr162 n = number of dependent sequences; and cxt~" number of sequences derived from the same germane sequence i. The number of dependent sequences (n) used to calculate the estimates was adjusted to account for repeat frequencies among either V. or VL sequences that deviated from the expected normal distribution (19) . For VL, n = 42, A = 14, and N = 861; therefore, the estimated number of V~ in the anti-DNA repertoire (R) is 62 (95% confidence interval [CI] = 43, 76). For V., n = 55, A = 34, and N = 1,485; therefore, R = 44 (95% CI = 31 and 63). For V.558, n = 28, A --16, and N = 378; therefore, R = 24 (95% CI = 15 and 36). Calculations of the probabilities that individual V. or V~ genes, or V,-V~ combinations, would be expressed at the indicated frequencies in the absence of selection among the population of hybridomas assumed a binomial distribution for any given V gene (20) .
Results
Oligoclonalit2/ of leG Anti-ONA Hybridomas. The criteria used in choosing mice for spleen cell fusions to generate hybridomas were age, serum titer, and isotype of spontaneous anti-DNA antibody. Mice used to generate IgM hybridomas were <6 mo of age, with IgG anti-DNA titers g90 and IgM anti-DNA titers )1,000. Mice chosen for generating IgG anti-DNA hybridomas were usuatly 6-8 mo old or older, with serum IgG anti-DNA titers )1,000. Hybridomas generated from the fusions were chosen for doming as described in Materials and Methods. This procedure was specifically chosen so as not to bias the population of hybridomas, particularly the IgM, toward either low-or high-affinity antibody. Specificity analyses of the mAbs in competitive ELISAs confirmed that there was no bias in the selection procedure for hybridomas producing either high-or low-affinity antibody (Table 1) . During the course of this study, 107 anti-DNA antibodyproducing hybridomas from 10 different autoimmune (NZB x NZW)F1 mice were generated. Each hybridoma was analyzed for VH and VL cDNA nudeotide sequences (Table 1,  and Figs. 1 and 2 ) and for isotype and DNA specificity of its respective mAb. In each mouse with predominantly IgG serum anti-DNA (mouse nos. 17, 111, 163, 10, 74, 83, and 185), the majority of the IgG hybridomas formed donally related groups. For the purpose of comparing the clonal repertoire between IgM and IgG anti-DNA antibodies among different individual mice, data in Table 1 and Figs. 1 and 2 are from only one representative hybridoma of a given donally related group. Clones with more than one hybridoma are indicated with a "c" designation as part of the clone number (e.g., 111-cl). For clones with more than one hybridoma, the number of hybridomas in each clone are indicated in Table  1 and Figs. 1 and 2. Clonal relatedness among relevant hybridomas was confirmed by nudeotide sequences, particularly in the junctional regions between V and D and D and J of the heavy chain, and V and J of the light chain, and by the identity of productive and nonproductive J. and J~ rearrangements within each donal member (21) . There were 38 IgM hybridomas from 36 clones, and 69 IgG hybridomas from 29 clones (Table 1) . Two clones had IgM and IgG hybridomas from the same clone. The degree to which individual clones were expanded in each of the mice was quite variable, from single representatives such as 17s.83 and 163.42 to clones with nine representative hybridomas such as clones 163-cl and 185-cl (Table 1) . There was considerable intraclonal variation due to somatic mutation in each of the multiple member clones ("c" clones in Table 1 ). Detailed analyses of the mutations and their effects on the specificity of the respective antibodies will be presented and discussed elsewhere (N.-T. Jou, D. Tillman, R. Hill, and T. Marion, manuscript in preparation).
Recurrent V~ Gene Usage among Both IgM and IgG Anti-DNA, Multiple clones from two or more animals expressed at least one V. gene from each of the V.558, V.7183, V~Q52, and V.$107 germline V. families (Table 1) . For example, 165.14 and 17s.128 each expressed a VH558 family V. gene that is nearly identical to the previously identified V. for the anti-DNA hybridoma BXW-DNA16 ( Fig. 1 A,  BWDNA16 ) (22) . Likewise, 17s-cl and 165.60 had nearly identical VK that are also similar to V.558-BWDNAI6, as did 10-cl and 17s.166, and 163.72 and 25.12m. Extreme examples of identical or nearly identical VH gene expression are clones 111.185, 165.27, 165.49, and 17s.83. These clones expressed a V~558 family V. gene very similar to that expressed by the previously identified anti-DNA hybridoma MLR-DNA22 ( Fig. 1 A, DNA22) (22) . Eight clones expressed a VH previously identified for the hybridoma BXW-DNA7 ( Fig. 1 A, BWDNA7 ). In the latter two groups of anti-DNA clones, four clones from three different mice ( Fig.  1 A, DNA22 ) and eight clones from four different mice ( Fig.  1 A, BWDNA7) , respectively, use the same V, gene.
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Tillman et al. Fig. 1 A, BWDNAT) . All the hybridomas in 111-c2 and three hyhridomas in 111-cl were IgG. Clone 17ps-c7 had two IgM hybridomas and one IgG hybridoma with a V, gene from the V,10 family (Table 1 and Fig. 3 ). In almost every case, at least one IgM and one IgG hybridoma expressed the same V. gene, usually with a different D~. Notable exceptions were two IgM-producing hybridomas, one of which had a VH derived from the V~606 family and the other from the VH36-60 family (Table 1 ). These two V. gene families were not represented among any of the IgG-producing hybridomas. Likewise, hybridomas expressing a V. from the VHSl07 family were found only among IgG-producing hybridomas (Table 1 and Fig. 2 ).
The estimated number of different germline V. genes that could encode an anti-DNA antibody is 44 (see Materials and Methods). The probability that four different clones out of the total of 63 would express a VH derived from the same germline V. gene by chance alone is 0.042. These results indicate that among the total population of clones there was preferential expression of V. genes homologous to the V.558 family genes expressed by the anti-DNA hybridomas MRL-DNA22 (111.185, 165.27, 165.49, 17s.83; Fig. 1 Fig. 1 A, BWDNAT) (22) . There was also preferential usage of a V.Q52-derived V. gene for which homologous V. genes have not been reported ( Fig. 1 C) .
Both the IgM and IgG anti-DNA hybridoma populations independently demonstrated preferential V. gene expression. The probability that three IgM clones cut out of the total of 36 would express a VH derived from the same germline V. gene by chance is 0.020. Therefore, there was a strong preference among the IgM hybridomas for V. genes homologous to genes from the V.Q52 family (four clones: 165.33, 165.41, 165.52, and 202.17; Fig. 1 C) . There was also preferential usage of a gene from the V.558 family similar to the V~ gene used by the anti-DNA hybridoma BXW-DNA7 (22) Fig. 1 A, BWDNA7) . IgM clones 165.60, 163.72, and 25.12m are >--92% homologous and use a V.558 family gene homologous to the previously described V, for the anti-DNA hybridoma BXW-DNA16 (22) .
As stated in the previous section, most of the hybridomas producing IgG anti-DNA was found to be members of clones represented by two or more hybridomas. Of the 29 clones represented among the 69 IgG hybridomas, 18 were represented by two or more hybridomas. If the analysis of preferential V. gene usage is determined on the basis of the frequency that a particular V. gene is used among IgG clones, there was preferential expression ~ <0.025) of a V~ homologous to the V.558 Vh31 germline gene (17s-c2, 165.3, and 74-cl; Fig. 1 A, S57 [Vh31]); and the V.S107 family Vhll 39 NB * The DNA binding specifidty for ssDNA and dsDNA is presented as the amount (/zg/ml) of either ssDNA or dsDNA that was required to produce 50% of maximum binding in the competitive ELISA. Numbers in italics represent values extrapolated from the inhibition curve. Percentages in italics are the maximum percentage inhibition of binding produced by 10/~g/ml competitor. The standard deviation of triplicate wells at each competitor dilution was always <10% of the mean OD40s. For clones with multiple bybridomas, the data presented are from one representative mAb. NI -no inhibition. EB = enhanced binding; in the presence of the competitor, binding to the solid-phase DNA was increased. * Clones represented by a single hybridoma are designated with a number. Clones with two or more members are designated by a "c" followed by a number. The number of individual hybridomas isolated and analyzed from a clone is in parentheses after each clone number. The "p" and "s" designations of the clones from animal 17 refer to the partial fusion from which the hybridomas were obtained (see text). "p" refers to the first fusion and "s" to the second. S Nomenclature according to Brodeur and Riblet (70) . II Amino acid sequence for that part of CDR3 contributed by D.. Nomenclature according to Potter et al. (71) . ** CDLP binding is presented as a ratio obtained by dividing the titer of mAb supernatant that produces 50% of maximum binding to CDLP in the solid-phase ELISA divided by the titer that produces 50% of maximum binding to DNA in the solid-phase ELISA for DNA binding. The dilution of supernatant that produced 50% maximum binding to solid-phase DNA was the same dilution used in each respective competitive ELISA for that supematant. NB = no binding. ** The cDNA sequence was not obtained.
germline gene (163-c2, 74-c2, and 111.33; Fig. 1 D) . If the estimation of preferential V. gene usage is based on the number of hybridomas rather than the number of clones, preference in V. gene usage was even stronger (p <0.004). Seven hybridomas expressed a V. homologous to V.558-BWDNA7 (111-cl and 111-c2; Fig. 1 A, BWDNA 7) . [9] [10] [11] [12] hybridomas expressed a V. homologous to V.Q52-165.33 (185-cl, 17s.145, and 163-c3; Fig. 1 C) ; and 12 hybridomas 765
Tillman et al. in this study, this V~ gene was found to be preferentially expressed among anti-DNA hybridomas from MLR lpr/ipr mice (9) . There was no apparent preferential expression of a particular J~ or V~-J~ combination among either IgM or IgG hybridomas.
Arginines in VH CDR3
Derived by Unusual DH Recombination. More than 50% of the clones, 35 of 63, had a VH with one or more arginines in CDR3 (Table 1 and Fig. 1 ). This is a highly characteristic feature of anti-DNA antibodies in mice (6, 7, 9, (22) (23) (24) (25) (26) (27) (28) (29) and humans (30, 31) . This region of the heavy chain is formed by recombination of one or more D~ genes within the 5' end of a J~ gene and the 3' end of a VH gene (32, 33) . Arginines are generally rare in CDR3 (9) and are the products of random events in the recombination process (24) . As we have demonstrated previously (7), arginines in VH CDR3 can be generated by several different mechanisms. These include N sequence addition (34, 35) , such as in 17p.73, 17s.93m, 163.100, and 202.105. A shift from the normal reading frame, RF1 (36, 37), of a DFL16 or Dsp2 gene to a different reading frame, RF3, can also generate arginines in VH CDR3. This frame shift can be caused either by N sequence addition, such as in 163.100 and 165.3 or DH-D~ recombination (33) or inversion of a Da gene during recombination, such as in 17s.13. AU these mechanisms for D region diversity have also been reported by others (9, 24, 38--40) .
Selected V~ Gene Expression among Both IgM and IgG H~ bridomas.
V~ from each of the V~I, V~2, V~4, V~5, V~8, V~9, VA0, V~12, V~19, V~20, V~21, and V~23 gene families and from the V~Ox-1, V~RF, Vxl, and Vx2 germline VL genes were expressed among the hybridomas analyzed in this study (Fig. 2) . The estimated number of different germline V~ genes that could be used to generate an anti-DNA antibody is 62 (see Materials and Methods). Based upon this number of V~ genes, the probability that three clones would express the same V~ gene is <0.018. Therefore, there was preferential usage of a V~ gene derived from each of the V~2 and V~5 germline families. The preferentially used V~2 gene was 92% homologous to the V~2 gene expressed by the previously identified anti-DNA hybridoma BXW-DNA14 (17p.3, 111-c2, and 17s.145; Fig. 2 C) (22) . The preferentially used V~5 gene was 92% homologous to the V~5 gene expressed by the anti-DNA hybridoma MRDDNA22 (163.72, 17s-cl, and 74-cl; Fig. 2 D) (22) . Preference for V~ derived from the VA and V~8 families was much stronger (p g0.000080) for seven or more clones expressing the same (95% homologous) VA or V~8 gene. The V~I genes expressed by all the clones in Fig. 2 A are ~>91% homologous to the V~I expressed by the previously reported anti-DNA hybridoma MRDDNA4 (22) . Most of the clones expressing a V~ gene from the V~8 group expressed a V,8 gene ~98% homologous to the V~ gene expressed by the anti-DNA hybridoma DNA5 from done 4 (7).
The preference for VA and V~8 was apparent among both IgM and IgG hybridomas ~ g0.0027 and p <0.00013, respectively). Among the IgM dories, five clones (17s.93m, 17p.101, 25.12, 111.185, and 165.27; Fig. 2 A) each expressed a VL derived from the same V,1 gene, and three clones (202.9, 165.45, 111-cl, and 165.5; Fig. 2 B) each expressed a VL derived from the same V,8 germline gene. Among IgG clones, four expressed a VL derived from the same VA germline gene (17s-c2, 17s-c3, 17s-c5, and 17s.13; Fig. 2 A) , and four expressed a VL derived from the same V~8 germline gene (165.49, 163-cl, 111-cl, and 165.3; Fig. 2 B) . These results indicate preferential clonal selection and expansion of anti-DNA B cells expressing either V~I or V~8 during both the early IgM and late IgG anti-DNA response in the autoimmune mice from which our panel of hybridomas was obtained.
JJ Junctional Diversity among VL of Anti-DNA Hybridomas. Assuming that each J~ has an equal probability for expression among anti-DNA B call clones, J~l was overrepresented and JA and J~5 were underrepresented among the clones listed in Table 1 Selection for V~,558-Vj and VH558-V~8. Assuming an equal probability for any of the possible anti-DNA VH genes to be expressed with any of the possible V~ genes in a given B cell, significantly more clones expressed VH-V~ combinations generated from a VH558 family V. and either a VA or V,8 family V~ than would have been expected if VH and VL genes assorted randomly (p <0.0018 for V~558-VA, and p <0.029 for V~558-V,8). When the data were analyzed to determine ff a particular VH gene-V~ gene combination was expressed at a higher-than-expected frequency among the clones, one combination was found to be preferentially used. The IgG hybridoma 17.s83 and the IgM hybridomas 111.185 and 165.27 expressed nearly identical V~ and VL genes. The VH gene was similar (~93% homology) to the V~558 family V~ gene previously reported for the anti-DNA hybridoma BXWAn "x" indicates sequence ambiguity for the relevant position. The sequences are numbered according to Kabat et al. (42) ; CDR regions are enclosed within rectangular boxes. The clone numbers of IgM-producing hybridomas are underlined. The nucleotide sequences from which these translated sequences were derived have been submitted to the EMBL/GenBank Sequences Libraries. The origin of the reference sequences are (A) the VH558 family VH genes for the anti-DNA hybridomas BXW-DNA16, MRL-DNA22, and BXW-DNA7 (22) and the V~ for the anti-DNA hybridomas 2F2 and $57 (Vh31) (9); (B) the VH7183 family germline gene Vh283 (9, 72) and the anti-DNA hybridoma DNA13 (7); (D) the V~$107 family germline gene Vhll (73) . ..................................... Fig. 1 A, BWDNA22) (22) . The V~ gene was the same (>198% homology) VK1 family gene previously reported for MRI:DNA4 (Fig. 2 A, MRLDNA4) . (Fig. 3) . The 17ps-c7 clone is particularly interesting. The hybridomas from this mouse are divided into p and s groups. The p group was generated (Fig. 3 A) . Clonality of these hybridomas was confirmed by identity of both productive and nonproductive J. and J, rearrangements (21) (not shown). The IgM hybridoma 111.19 and the IgG hybridomas 111.61, 111.100, and 111.109 from clone 111-cl were also found to be clonaUy related, although these hybridomas were all generated in the same fusion (Fig.  3 B) . Somatic mutations were apparent in both clones. The effects of these mutations on specificity for DNA will be discussed elsewhere (Jou et al., manuscript in preparation The mAb produced by each hybridoma was assayed for specificity of binding to ssDNA, dsDNA, and cardiolipin (CDLP) t (Table 1) . Although all the mAbs bound to DNA in a direct ELISA (Materials and Methods), a small number (8 IgM mAbs out of 107 total mAbs) were not competitively inhibited by either ssDNA or dsDNA in the competitive ELISA. This may be a reflection of the higher avidity of these antibodies for binding to immobilized DNA. In fact, six of the IgM mAbs (17p.3, 111.68, 165.33, 165.41, 165 .52, and 202.80) that were not competitively inhibited demonstrated increased binding to the solid-phase DNA in the presence of competitor DNA (Table 1 ). The most likely explanation for this observation is that these antibodies have relatively low affinity for binding to DNA. In the presence of competitor and because of the high avidity of IgM, the antibodies are able to form a lattice that stabilizes their binding to the immobilized DNA. There was no significant relationship between particular V, or VL gene expression by different hybridomas and the absolute ability of the antibodies from those clones to bind to ssDNA vs. dsDNA or CDLP (0.05 <p <0.10). Likewise, there was no correlation between arginines in VH CDR3 and specificity for DNA among the antibodies. However, as discussed below, the position of argipines in VH CDR3 had a remarkable effect on the DNA specificity of the respective mAb; and particular VH and VL structural combinations also had demonstrable effects on DNA specificity. All of the mAbs that had an argipine at position 96 in VL bound to dsDNA. As indicated above, arginine at this position was most likely derived from junctional diversity in V~ to J~l recombination. The recurrent nature of this randomly generated structure among clones using J~l suggests that this structure may have been specifically selected. This possibility is supported by results from a comparison of mAbs 111.185 and 165.27. Although both mAbs bind to ssDNA very well (Table 1) , 111.185 binds poorly but measurably and consistently to dsDNA. These two antibodies differ in VH and VL at only two identifiable positions. 111.185 has an isoleucine instead of valine at position 94 in VL CDR3. More importantly, 111.185 has an arginine instead of tryptophan at position 96 in VL CDR3.
DNA22 (
There was a very interesting and highly significant trend relative to the specificity of antibodies produced by IgM vs. IgG clones. A significantly higher percentage of IgG clones produced antibody that bound to both ss-and dsDNA or dsDNA alone as opposed to ssDNA binding alone (Table  1) . Of 27 IgG clones, 21 had one or more hybridomas that produced anti-dsDNA antibody, compared with 12 of 34 IgM clones (p <0.001). This difference was even more pronounced when individual hybridomas rather than clones were compared (p <0.0005). The difference in dsDNA binding between IgM and IgG mAbs was also observed within a single done, 17ps-c7. The IgM mAbs 17p.79 and 17p.80 both bound to ssDNA with relatively high avidity but did not bind to dsDNA 0ou et al., manuscript in preparation). The IgG mAb from the donally related hybridoma 17s.161, obtained 1.5 mo later, bound to ssDNA and dsDNA.
Discussion
The results from our analyses of the hybridomas described above confirm our previously reported results that the IgG anti-DNA hybridomas from an individual (NZB x NZW)-F1 mouse were oligodonal and somatically mutated (6, 7), and therefore had the characteristics of secondary immune antibodies (21, (44) (45) (46) (47) (48) . The present results indicate that the oligoclonality of IgG anti-DNA hybridomas observed previously was not unique to a single mouse and may, in fact, be a general characteristic of IgG anti-DNA hybridomas obtained from individual (NZB x NZW)F1 mice. These results corroborate the hypothesis that the spontaneous IgG anti-DNA antibody response characteristic of these mice is generated as a donally selective, Ig receptor-specific immune response. IgG anti-DNA hybridomas from MRL lpr/Ipr mice are also oligodonal and the mAbs from those hybridomas are characteristic of secondary immune antibodies (8, 9, 25) . Oligodonality of IgG anti-DNA antibodies has also been observed among anti-DNA mAbs from autoimmune (NZB x SWIL)F1 mice (27) and among V,11 encoded anti-DNA in (NZB x NZW)F1 mice (28) .
The IgM anti-DNA hybridomas from the mice in this study also appear to have been derived from B cells that were stimulated in a donally sdective, antigen-specific manner. This conclusion is based on the statistical analyses of V, and VL gene expression among the IgM clones. Even though each of the 44 V~ and 62 VL germline genes in the estimated anti-DNA V gene repertoire could encode an anti-DNA antibody, two V, and two V~ genes were each expressed in a much larger number of IgM hybridomas than would have been expected in the absence of antibody receptor-mediated selection. The preferential V gene expression among IgM hybridomas was not the end result of the process by which hybridomas were chosen for doping since the only criterion used was the ability of the antibody in the respective fusion well to bind DNA. Based upon the results from the competitive ELISA used to test the specificity of each mAb (Table 1) , the selection of hybridomas for doping was not biased with respect to the specificity or at~nity of the respective mAbs. As the results in Table I clearly demonstrate, hybridomas producing both high-and low-at~pity mAb were represented in our sample. We (4) and others (49) have demonstrated that the hybridomas obtained from autoimmune mice are representative of the serum antibody in the fusion donor.
This report provides the first demonstration that both IgM and IgG anti-DNA antibodies within individual autoimmune mice may be derived from the same B cell clones. The results demonstrate that the V regions of IgM and IgG anti-DNA antibody in autoimmune (NZB x NZW)F1 mice are structurally similar. Also, the V~ and VL genes that were preferentially expressed among the IgM anti-DNA hybridomas were also preferentially expressed among the IgG hybridomas. Within individual mice, both IgM and IgG anti-DNA antibodies may be produced by donally related B cells. Therefore, B cells that are selectively stimulated to produce the IgM anti-DNA seen early in autoimmune (NZB x NZW)F1 mice may differentiate and clonally expand to generate the IgG anti-DNA seen later in the same mice. In addition, the results demonstrate that there was greater specificity for dsDNA binding among the IgG mAbs than the IgM. This may indicate preferential selection for dsDNA specificity among B cell clones that are stimulated to expand and differentiate to IgG production. The results suggest that the stimulus for this B cell clonal expansion may be native DNA. The results are also consistent with and may explain the observed progression of anti-DNA autoantibody in both mouse and human lupus from more ssDNA-specific to more dsDNAspecific antibody (1, 3) . Taki et al. (50) have likewise isolated an IgM hybridoma from an (NZB x NZW)F1 mouse that may be clonally related to an IgG hybridoma from the same mouse. The IgG mAb had much higher avidity for dsDNA than the IgM mAb. The VH used by both hybridomas was the same, and H chain rearrangements in the two hybridomas were the same. However, since the authors did not analyze the respective hybridomas for either L chain sequences or rearrangements, the clonal relatedness of the two hybridomas cannot be assured.
Results from previous studies of B cell activity and antibody production in autoimmune (NZB x NZW)F1 mice led to the hypothesis that anti-DNA antibody was a byproduct of polyclonal B cell activation (reviewed in reference 14). In light of the results from analyses of the effect of the host environment in which B cells develop on the ontogeny of anti-DNA autoantibody (15, 51) and the clonotypic analyses of IgG anti-DNA antibodies in autoimmune mice (6, 8) , this hypothesis has recently been modified to propose that the early, IgM anti-DNA B cells are polyclonally activated and that antigen-specific (DNA) selection occurs subsequent to this event (14) . This process would yield IgM anti-DNA with the structural characteristics of a randomly selected population of DNA-specific antibodies and IgG anti-DNA with the structural characteristics of a clonally selected population of antibodies. Our results are not consistent with this hypothesis. Although the results cannot exclude the existence of a population of polyclonally activated B cells in the (NZB x NZW)F1 mice used in this study, they suggest that both the IgM and IgG anti-DNA hybridomas were derived from B cells stimulated by antibody receptor-specific events. As discussed below, those events were probably antigen-specific stimulation, most likely by DNA or complexes containing DNA.
Previous analyses of V gene diversity among autoimmune anti-DNA antibodies have demonstrated preferential expression of V. genes from the V.558 family (9, 25, 52) . Radic et al. (25) estimated that 15 V8558 genes may encode anti-DNA (95% C1 = 9, 42). Using the identical pair method (18), we estimated the number of V8558 genes that could encode anti-DNA to be 24 (95% CI = 15, 36), which agrees reasonably well with the previous estimate. The recurrence of particular V, genes among the anti-DNA hybridomas analyzed in this study is striking particularly when compared with the V. gene expression seen among anti-DNA hybridomas in previously published studies. A summary of the recurrence of VH and V~ genes among all previously published spontaneous anti-DNA antibody variable region sequences is presented in Tables 2 and 3 . The V, genes that were preferentially expressed among the hybridomas sequenced in this study have been recurrent among the anti-DNA antibodies sequenced in other laboratories. Moreover, even the V. genes that were not preferentially expressed among our population of hybridomas are recurrent among the total murine population of anti-DNA antibodies for which VH sequences have been published (Table 2 ). Preferential expression of VL genes that has not previously been apparent among anti-DNA (9, 25) could be identified here, because of the larger number of sequences analyzed in this study (Fig. 2) . Those VL genes that are preferentially expressed among the hybridomas in this study are recurrent among the total population of mouse spontaneous anti-DNA for which VL sequences have been reported (Table 3 ). Like the V. genes, even those V~ genes that were not preferentially expressed among our population of hybridomas are recurrent in the total population of mouse spontaneous anti-DNA. The V.558-VK1 and V,558-V~8 combinations that were preferentially expressed among the hybridomas analyzed in our studies have also been observed among previously analyzed anti-DNA hybridomas (7) (8) (9) 24) .
The recurrent nature of particular V.-V~ combinations and individual V, and VL genes, as described above, is indicative of a strong preference for these variable region structures among anti-DNA hybridomas. The rather large number of V. and Vc genes that can potentially generate an anti-DNA antibody indicates that there is no V, or Vc gene restriction for the generation of these antibodies. Even the most highly represented V. and VL genes were found in only 13% and 11% of the clones, respectively. Rather, the recurrent and preferential use of particular Va-VL combinations is more consistent with clonal selection of anti-DNA B cells through antibody receptor-mediated events. As discussed below, the most likely event to control such selection is antigen-specific selection by DNA or DNA complexes. The lack of V. and Vc restriction is consistent with results from previous studies of V. gene diversity among anti-DNA hybridomas from an individual (NZB x NZW)Fx mouse (10) and from MILL Ipr/lpr mice (9) . Therefore, as previously discussed in detail (7, 9) , shared idiotypy among anti-DNA (5, 53-57) is unlikely to result from V. or V~ gene restriction. Rather, shared idiotypy among anti-DNA is more likely related to structures that control the specificity of anti-DNA (9) .
All the clones with the junctionally derived arginine in JK1 produce anti-DNA antibodies that bind dsDNA (Table  1 , and Jou et al., manuscript in preparation). Moreover, this same J~l arginine has appeared in the anti-DNA hybridoma DNA4 and the clonally related hybridomas DNAS, DNA6, and DNA7 from our laboratory, and among anti-DNA hybridomas from other laboratories: B62 (29) and BxW-DNA14 (22) from (NZB x NZW)Fg 13 and 30 from (SWR x NZB)F1 no. 7 (27) ; and 2Bll from BALB/c (58) . All the monoclonal anti-DNA with J~l that have arginine at position 96 bind dsDNA. These results suggest that arginine at position 96 in VL CDR3 may be a highly selected structure, especially for dsDNA binding. The canonical L chain for Id TM antiarsonate antibodies also has an arginine at position 96 in VL CDR3 that appears to be generated from junctional diversity (59) . This VL structure is highly selected among antiarsonate antibodies. Arginines in both VH CDR3 and position 96 VL CDR3 are generated by random, nontemplate-encoded processes (7, 9, 24, 25, 29) and are relatively rare among antibodies in general (9) . Therefore, there Fig. 1 . Relevant sequences from Fig. 1 are clones that share the indicated V gene sequence. S The clones or hybridomas indicated (from previous publications indicated by the reference) are homologous to the indicated V region sequence. must be a strong selection for DNA-specific B cells with antibody receptors that have arginines at these positions.
Because of its basic charge and potential ability to form hydrogen bonds with either G-C base pairs through the major groove or phosphate groups on the backbone of dupl~ DNA, arginine has been predicted to be important for protein binding to DNA (60) . Direct evidence for such a role of arginine in anti-DNA mAb BV04-01 has been demonstrated (61) . Therefore, sdection for one or more arginines in VH CDR3 and at position 96 in VL CDR3 may occur because arginines at these positions increase the potential for DNA binding by the respective antibodies. Mutations that result in arginine replacements in VH CDR have been demonstrated to have marked effects on the specificity and relative af~nity of anti-DNA antibodies (7, 8, 25 , and Jou et al., manuscript in preparation). Moreover, the most frequent replacement mutations among anti-DNA antibodies are to arginine or asparagine (25) , another amino acid predicted to be particularly impor- In light of these observations, the comparison of consensus VH and VL CDR sequences generated from all of the mAbs in this study generates very interesting results. To generate these results, all of the mAbs in Table 1 petitively inhibited by g2/~g/ml dsDNA. Of the 107 mAbs, seven were not included because either the VH or VL sequence was incomplete for e'~.h. The VH and VL CDR amino acid sequences for the mAbs in each of the three groups were aligned (42) , and consensus CDR sequences for both VH and VL were generated for each group. Since there were two large clones in the dsDNA group (163-cl and t85-cl), consensus CDR sequences were also separately generated for the dsDNA mAbs according to V. gene family expression to determine how the large clones might bias the dsDNA consensus. 163-cl has a V.7183 V., and 185-cl, a VaQ52 V.. As the results demonstrate (Fig. 4) , the consensus VH and VL were representative of more than just the large clones.
Comparison of the consensus CDR sequences for the three specificity groups of anti-DNA mAbs (Fig. 4) reveals that the loDNA group of mAbs was the most variable. The ssDNA group and dsDNA group have very similar consensus VH CDR1 and two but considerably different VH CDR3. Most interesting are the consensus arginines at positions 100 and 100a in the dsDNA group. The consensus arginines at positions 100 and 100a do not necessarily imply that most dsDNA-specific mAbs in our population have arginines at both positions. Rather, as the consensus for each V. family demonstrates, most of the antibodies have arginine at one or the other position. Although 7 of 16 loDNA and 25 of 46 ssDNA mAbs also have arginines in VH CDR3, the arginines in VH CDR3 among these two groups are more randomly distributed. The anti-DNA mAb from DNA3, DNA4, and all the hybridomas in clone 3 previously analyzed in our laboratory (7) have arginines at one or both positions 100 and 100a in VH CDR3, and they all bind to dsDNA with high avidity. Several anti-DNA mAbs from other laboratories that bind to dsDNA also have one or more arginines at positions 100 to 100a in VH CDIL3: clone F (9); done 1 (28); and B62 and C72 (29) . Although 24 of 38 IgG dsDNAbinding mAbs indicated in Table 1 have arginines in VH CDR3 between positions 99 and 100b, there are exceptions. Of the exceptions, only four have VH CDR3 without arginines.
The comparison of consensus VL CDK sequences indicates that the loDNA VL consensus is very similar to that for the dsDNA group, with the exceptions of position 29 in VL CDR1, position 55 in CDR2, and positions 89 and 93 in CDR3. The consensus VLs for both the IoDNA and dsDNA groups are similar to the V~8 sequence of DNA5 (Fig. 2 B) , with the differences noted above. The consensus VL for the ssDNA group is nearly identical to that of VA (Fig. 2 A) . These consensus sequences are consistent with the binding specificities of the antibodies in the respective groups. Of 20 mAbs with a VK8 VL, 12 bind strongly to dsDNA, while only 1 of 26 mAbs with a VK1 VL binds strongly to dsDNA (Table 1 , and Jou et al., manuscript in preparation). Five mAbs with V,5 VL also bind to dsDNA very well (Table 1 , andJou et al., manuscript in preparation). Of the five V,5 mAbs, four have an arginine at position 29 in VL CDR1 analogous to the V~8 mAbs that bind to dsDNA strongly (Fig. 2, B and D) . The mAb from 202.135 and all of those from the hybridomas in clone 111-cl have V,558-BWDNA7 and V~8-DNA5 (Figs. 1 A and 2 B) . The VH CDK3 for both clones are similar as well. The mAbs from 111-cl all bind dsDNA (Jou et al., manuscript in preparation), whereas the mAb from 202.135 only binds to ssDNA. Given the above results, the difference in VL CDR1 position 29 between these two clones may contribute in part, if not totally, to the difference in DNA binding by these mAbs, although there are other sequence differences between these two clones. A notable position in the consensus for dsDNAbinding mAbs with VH from the V.558 family is position 96 in VL CDR3. The consensus for this group at that position is an arginine. As detailed above, arginine at this position is probably generated by junctional diversity in the first codon of J~l.
The VH and VL CDR sequences for the mAbs from clone 163-cl are nearly identical to the consensus sequences for V,7183 dsDNA-binding antibodies (Fig. 4) . Of nine mAbs from this clone, eight bind to dsDNA with relatively high avidity ( Table 1 , and Jou et al., manuscript in preparation). A computer model of one of the mAbs from clone 163-cl, 163.1, was generated using the crystallographic coordinates for the antilysozyme mAb HyHEL5 (62) (Fig. 5) . The hypothetical binding of a model of poly(dA-dT)-poly(dAdT) to the antibody-combining site was obtained by docking the DNA with the antibody-combining site. This DNA forms a normal B form double helix. The amino acids predicted by the computer model to be in positions to form hydrogen bonds with either base pair or backbone structures of the DNA are identified in Fig. 5 . As the model illustrates, lysine at position 50, serine at position 52a, and arginine at position 100 in the heavy chain, and arginine at position 29 and asparagine at position 31 in the light chain, are each in a position that would allow them to form hydrogen bonds with phosphate oxygens on the DNA backbone. The arginines in VH position 100 and VL Position 29 correspond to residues that were predicted by the dsDNA group consensus sequence (Fig. 4) to be important for dsDNA binding. Among the eight hybridomas clonally related to 163.1, a shared somatic mutation at VH position 50 and a unique mutation at VH Position 52a can be directly correlated to differences in dsDNA binding by the respective mAbs (Jou et al., manuscript in preparation). Therefore, the amino acids predicted by the hypothetical model to be responsible for DNA binding by mAb 163.1 are the same ones that have been predicted to be important for dsDNA binding by structural and serological analyses of the mAbs from clone 163-cl.
The pathogenetic potential of the mAbs described in this report to initiate autoimmune disease has not been directly tested. O'Keefe et al. (63) have used the criterion of variable region cationicity, characteristic of antibodies expressing the Id564 idiotype, as an indicator of pathogenicity. Based upon this criterion, many of the mAbs described here and certainly the antibodies that bind to dsDNA with relatively high avidity would be expected to be pathogenic, as would most of the dsDNA-binding antibodies that have been reported by others, such as A52 (24), mAbs from clone A (9), and mAbs from clone H (25) . This criterion is certainly consistent with the original observations of Ebling and Hahn (64) and Dang and Harbeck (65) that the anti-DNA antibodies deposited in nephritogenic mouse kidneys are cationic. The selection for basic amino acids within the V regions of most anti-DNA antibodies demonstrated here and by others (6, 7, 9, 24, 25, 29) may account for the cationicity of pathogenic anti-DNA antibodies. Of those anti-DNA mAbs that have been directly demonstrated to initiate or accelerate nephritis, H130 (66), A6.1, and 3GB3 (67) have a neutral pI. Therefore, determination of pathogenicity among anti-DNA mAbs cannot be related only to pI or idiotype expression (66, 67) . Moreover, the formation of glomerular immune deposits by the mAbs H130, H241 (66) , and A52 (68) were independent of DNA binding by the mAbs. These observations lead to the interesting hypothesis that the production of anti-DNA antibody is induced and sustained by DNA or DNA complexes, but pathogenesis may occur independently of DNA binding. Clearly future experiments will be needed to sort out the structural basis for the pathogenicity of anti-DNA antibody in lupus nephritis.
The most common feature among anti-DNA antibodies as demonstrated here and elsewhere (6-9, 24-27, 29, 69) is the selective expression of VH and VL structures that would be predicted and in some cases can be demonstrated to influence specificity for DNA. Although these results cannot rule out other structurally selective mechanisms such as idiotype networks and DNA crossreactive antigens that may contribute to the generation of anti-DNA, they are most consistent with the hypothesis that anti-DNA originates and is sustained by an antigen-specific immune response to DNA, most likely in a complex with proteins that could provide the necessary source for a T, epitope.
